KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ANCA-IgG-positive ANCA Associated Vasculitis
Conditions
ANCA-IgG-positive ANCA Associated Vasculitis
Trial Timeline
Jan 1, 2025 → Jul 1, 2027
NCT ID
NCT06590545About KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy is a phase 1/2 stage product being developed by Kyverna Therapeutics for ANCA-IgG-positive ANCA Associated Vasculitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06590545. Target conditions include ANCA-IgG-positive ANCA Associated Vasculitis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06590545 | Phase 1/2 | Recruiting |
Other Products from Kyverna Therapeutics
Standard of Care Treatment + Standard lymphodepletion regimen + KYV-101Phase 2/3
57
Standard lymphodepletion regimenPhase 2
44
KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mABPhase 2
44
KYV-101 anti-CD19 CAR-T cell therapy + Standard lymphodepletion regimenPhase 1/2
33
KYV-101 + Standard lymphodepletion regimenPhase 1/2
33